Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) has announced that its board of directors will convene on 28 April 2026 to consider and approve the consolidated results for the three months ended 31 March 2026, along with the formal release of the first-quarter report.
The notification, dated 10 April 2026, outlines that Chairman Chen Yuqing will preside over the session. The board currently comprises five executive directors, two non-executive directors, four independent non-executive directors, and one employee director, underscoring a broad governance structure ahead of the upcoming earnings review.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments